科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点

智通财经07-15

【科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点】科伦药业公告，控股子公司科伦博泰核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的3期临床研究，在预设期中分析中经独立数据监查委员会确认达到无进展生存期主要终点，相比化疗联合帕博利珠单抗显示出统计学和临床意义显著改善，总生存期有获益趋势，安全性良好。科伦博泰计划就该研究结果...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2651436406?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-15 11:58","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2651436406","market":"us","top_or_hot":-1,"title":"科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点","media":"智通财经","content":"<div>\n<p>【科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点】科伦药业公告，控股子公司科伦博泰核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的3期临床研究，在预设期中分析中经独立数据监查委员会确认达到无进展生存期主要终点，相比化疗联合帕博利珠单抗显示出统计学和临床意义显著改善，总生存期有获益趋势，安全性良好。科伦博泰计划就该研究结果...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-15 11:58 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点】科伦药业公告，控股子公司科伦博泰核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的3期临床研究，在预设期中分析中经独立数据监查委员会确认达到无进展生存期主要终点，相比化疗联合帕博利珠单抗显示出统计学和临床意义显著改善，总生存期有获益趋势，安全性良好。科伦博泰计划就该研究结果...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4231","symbol_name":"零售房地产信托","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2651436406","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651436406","pubTimestamp":1784087937,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点】科伦药业公告，控股子公司科伦博泰核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4231":"零售房地产信托","NETL":"NETLease Corporate Real Estate ETF","BK4080":"零售业房地产投资信托","ADC":"艾格里房产"},"translate_title":"Kelun Pharmaceutical: TROP2 ADC combination therapy for lung cancer phase 3 clinical trial reaches primary endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NETL":0.6,"ADC":1.5},"content_text":"【科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点】科伦药业公告，控股子公司科伦博泰核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的3期临床研究，在预设期中分析中经独立数据监查委员会确认达到无进展生存期主要终点，相比化疗联合帕博利珠单抗显示出统计学和临床意义显著改善，总生存期有获益趋势，安全性良好。科伦博泰计划就该研究结果与国家药监局药品审评中心进行沟通。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651436406","isCrawlerRequest":true}